AGEN - Agenus Inc.
| Previous Close | 3.0700 |
| Open | 3.0900 |
| Bid | 3.0000 x 3200 |
| Ask | 3.0800 x 3100 |
| Day's Range | 3.0200 - 3.1150 |
| 52 Week Range | 1.5400 - 3.8800 |
| Volume | 566,695 |
| Avg. Volume | 999,249 |
| Market Cap | 417.431M |
| Beta (3Y Monthly) | 1.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9060 |
| Earnings Date | Jul 28, 2017 - Jul 31, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- Zacks
Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Before You Buy Agenus Inc. (NASDAQ:AGEN), Consider Its Volatility
If you own shares in Agenus Inc. (NASDAQ:AGEN) then it's worth thinking about how it contributes to the volatility of...
- Thomson Reuters StreetEvents
Edited Transcript of AGEN earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Agenus Inc Earnings Call
Motley FoolAgenus Inc (AGEN) Q2 2019 Earnings Call Transcript
AGEN earnings call for the period ending June 30, 2019.
- Zacks
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
- Zacks
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Agenus Milestone Triggers $7.5M Payment
LEXINGTON, Mass., Aug. 8, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the company's IND filing for AGEN2373, a milestone in its partnership with Gilead Sciences, Inc. This milestone triggers a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments this year and beyond.
- PR Newswire
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019 - Second generation CTLA-4 advances in clinic; data expected 2H2019 - Launched commercial readiness with head of commercial on board ...
- PR Newswire
Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day. The call will also be webcast and will be accessible from the Company's website at http://investor.agenusbio.com/presentation-webcasts or with this link https://www.webcaster4.com/Webcast/Page/1556/31262.
- Simply Wall St.
Is Agenus (NASDAQ:AGEN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
- PR Newswire
Agenus Appoints Don Vidic as Vice President and Head of Commercial
LEXINGTON, Mass., July 18, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial. "Don has deep expertise in market access and distribution strategies and shares our commitment to disruptive commercial models designed to provide access to all patients who need our products," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We have built a unique ecosystem which has allowed us to innovate with speed and set new records in drug discovery and development. We are on track to submit our first BLA filing for our lead CTLA-4 and PD-1 molecules in 2020.
- Zacks
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
- Simply Wall St.
How Many Agenus Inc. (NASDAQ:AGEN) Shares Do Institutions Own?
If you want to know who really controls Agenus Inc. (NASDAQ:AGEN), then you'll have to look at the makeup of its share...
- Zacks
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
- PR Newswire
Agenus to Host Annual Meeting of Stockholders
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
- Thomson Reuters StreetEvents
Edited Transcript of AGEN earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Agenus Inc Earnings Call
- Zacks
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point
MARIETTA, Ga., May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm.
- Zacks
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
- Zacks
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Motley FoolAgenus Inc (AGEN) Q1 2019 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2019.
- Zacks
Agenus (AGEN) Surpasses Q1 Earnings Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Agenus: 1Q Earnings Snapshot
The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...
- PR Newswire
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...
